Featured News
news cover
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
6 hours ago
news cover
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
6 hours ago
news cover
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
6 hours ago
news cover
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
6 hours ago
View more
Global Express
3 hours ago
New York biotech gets ex-China rights to hyperthyroidism mAb in $1.4B deal
License out/in
4 hours ago
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
Phase 3
6 hours ago
Millions Set to Lose Healthcare Coverage in 2026 as Policy Shifts Accelerate; Prescription Hope Keeps Brand-Name Medications Within Reach for Americans
7 hours ago
Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
Drug ApprovalImmunotherapyBiosimilar
7 hours ago
Aussie medtech Ferronova raises another $6 million to advance image-guided cancer surgery
View more
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
May 2025 Patent Highlights
May 2025 Patent Highlights
Patsnap Synapse
JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics
JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics
Patsnap Synapse
Global Drug R&D Express (February 2025)
Global Drug R&D Express (February 2025)
PatSnap Synapse
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.